ORGN 54-Discovery of potent, selective, and orally bioavailable antagonists of CC Chemokine Receptor 2

被引：0

作者：

Carter, Percy H. ^{[1
]}

Brown, Gregory D. ^{[1
]}

Nelson, David J. ^{[1
]}

Cherney, Robert J. ^{[1
]}

Duncia, John V. ^{[1
]}

Santella, Joseph B., III ^{[1
]}

Gardner, Daniel S. ^{[1
]}

Cvijic, Mary Ellen ^{[2
]}

Mandlekar, Sandhya ^{[3
]}

Tebben, Andrew J. ^{[4
]}

Zhao, Qihong ^{[5
]}

Decicco, Carl P. ^{[1
]}

Barrish, Joel C. ^{[1
]}

机构：

[1] Bristol Myers Squibb Res & Dev, Discovery Chem, Princeton, NJ 08543 USA

[2] Bristol Myers Squibb Res & Dev, Lead Evaluat, Princeton, NJ 08540 USA

[3] Bristol Myers Squibb Res & Dev, Metab & Pharmacokinet, Princeton, NJ 08540 USA

[4] Bristol Myers Squibb, Comp Assisted Drug Design, Princeton, NJ 08543 USA

[5] Bristol Myers Squibb Res & Dev, Immunol Biol, Princeton, NJ 08540 USA

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2008年 / 236卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

54-ORGN

引用

页数：1

共 50 条

[31] The discovery of potent, orally bioavailable pyrimidine-5-carbonitrile-6-alkyl CXCR2 receptor, antagonists
Porter, David W.
Bradley, Michelle
Brown, Zarin
Charlton, Steven J.
Cox, Brian
Hunt, Peter
Janus, Diana
Lewis, Sarah
Oakley, Paul
O'Connor, Des
Reilly, John
Smith, Nichola
Press, Neil J.
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (15) : 3285 - 3290
[32] Discovery of a Novel Class of Potent and Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists
Ibrahim, Mohamed A.
Johnson, Henry W. B.
Jeong, Joon Won
Lewis, Gary L.
Shi, Xian
Noguchi, Robin T.
Williams, Matthew
Leahy, James W.
Nuss, John M.
Woolfrey, John
Banica, Monica
Bentzien, Frauke
Chou, Yu-Chien
Gibson, Anna
Heald, Nathan
Lamb, Peter
Mattheakis, Larry
Matthews, David
Shipway, Aaron
Wu, Xiang
Zhang, WenTao
Zhou, Sihong
Shankar, Geetha
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (03) : 1368 - 1381
[33] Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1
Liang, M
Mallari, C
Rosser, M
Ng, HP
May, K
Monahan, S
Bauman, JG
Islam, I
Ghannam, A
Buckman, B
Shaw, K
Wei, GP
Xu, W
Zhao, Z
Ho, E
Shen, J
Oanh, H
Subramanyam, B
Vergona, R
Taub, D
Dunning, L
Harvey, S
Snider, RM
Hesselgesser, J
Morrissey, MM
Perez, HD
Horuk, R
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (25) : 19000 - 19008
[34] Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist
Scott, James S.
Moss, Thomas A.
Balazs, Amber
Barlaam, Bernard
Breed, Jason
Carbajo, Rodrigo J.
Chiarparin, Elisabetta
Davey, Paul R. J.
Delpuech, Oona
Fawell, Stephen
Fisher, David, I
Gagrica, Sladjana
Gangl, Eric T.
Grebe, Tyler
Greenwood, Ryan D.
Hande, Sudhir
Hatoum-Mokdad, Holia
Herlihy, Kara
Hughes, Samantha
Hunt, Thomas A.
Hoan Huynh
Janbon, Sophie L. M.
Johnson, Tony
Kavanagh, Stefan
Klinowska, Teresa
Lawson, Mandy
Lister, Andrew S.
Marden, Stacey
McGinnity, Dermot F.
Morrow, Christopher J.
Nissink, J. Willem M.
O'Donovan, Daniel H.
Peng, Bo
Polanski, Radoslaw
Stead, Darren S.
Stokes, Stephen
Thakur, Kumar
Throner, Scott R.
Tucker, Michael J.
Varnes, Jeffrey
Wang, Haixia
Wilson, David M.
Wu, Dedong
Wu, Ye
Yang, Bin
Yang, Wenzhan
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (23) : 14530 - 14559
[35] Discovery of potent, orally bioavailable CCR5 antagonists - 1.
Tagat, J
Nazareno, D
Vice, S
Lin, S
Steensma, R
Miller, M
Bauer, A
McCombie, S
Palani, A
Josien, H
Clader, J
Neustadt, B
Greenlee, W
Ganguly, A
Piwinski, J
Chan, TM
Evans, A
Dan, N
Baroudy, B
Endres, M
Strizki, J
Vantuno, N
Cox, K
Broske, L
Zhang, X
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U5 - U5
[36] Discovery of potent and orally bioavailable CCR5 antagonists: Part I
Wei, Robert G.
Chen, Binglong
Dunning, Laura
Ho, Elena
Jaroch, Stefan
Lee, Wheeseong
Onuffer, James
Subramanyam, Babu
Shen, Jun
Tseng, Jih-Lie
Ye, Bin
Gary, Phillips
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 596 - 596
[37] Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2
Nguyen, Minh H.
Atasoylu, Onur
Wu, Liangxing
Kapilashrami, Kanishk
Pusey, Michelle
Gallagher, Karen
Lai, Cheng-Tsung
Zhao, Peng
Barbosa, Joseph
Liu, Kai
He, Chunhong
Zhang, Colin
Styduhar, Evan D.
Witten, Michael R.
Chen, Yaoyu
Lin, Luping
Yang, Yan-ou
Covington, Maryanne
Diamond, Sharon
Yeleswaram, Swamy
Yao, Wenqing
[J]. ACS MEDICINAL CHEMISTRY LETTERS, 2022, : 1159 - 1164
[38] Discovery of chiral dihydropyridopyrimidinones as potent, selective and orally bioavailable inhibitors of AKT
Parthasarathy, Saravanan
Henry, Kenneth
Pei, Huaxing
Clayton, Josh
Rempala, Mark
Johns, Deidre
De Frutos, Oscar
Garcia, Pablo
Mateos, Carlos
Pleite, Sehila
Wang, Yong
Stout, Stephanie
Condon, Bradley
Ashok, Sheela
Lu, Zhohai
Ehlhardt, William
Raub, Tom
Lai, Mei
Geeganage, Sandaruwan
Burkholder, Timothy P.
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (10) : 1887 - 1891
[39] Biarylpyrazolyl Oxadiazole as Potent, Selective, Orally Bioavailable Cannabinoid-1 Receptor Antagonists for the Treatment of Obesity
Lee, Suk Ho
Seo, Hee Jeong
Lee, Sung-Han
Jung, Myung Eun
Park, Ji-Hyun
Park, Hyun-Ju
Yoo, Jakyung
Yun, Hoseop
Na, Jooran
Kang, Suk Youn
Song, Kwang-Seop
Yim, Min-ah
Chang, Chong-Hwan
Kim, Jeongmin
Lee, Jinhwa
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (22) : 7216 - 7233
[40] Discovery of potent, selective, orally active benzoxazepine-based Orexin-2 receptor antagonists
Fujimoto, Tatsuhiko
Kunitomo, Jun
Tomata, Yoshihide
Nishiyama, Keiji
Nakashima, Masato
Hirozane, Mariko
Yoshikubo, Shin-ichi
Hirai, Keisuke
Marui, Shogo
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (21) : 6414 - 6416

← 1 2 3 4 5 →